Get the Stockscreener App
4.37
9.34%
-0.45
After Hours:
4.37
Camp 4 Therapeutics Corp stock is traded at $4.37, with a volume of 25,617.
It is down -9.34% in the last 24 hours and down -4.59% over the past month.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$4.82
Open:
$4.98
24h Volume:
25,617
Relative Volume:
0.25
Market Cap:
$92.74M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-1.0669
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
-9.15%
1M Performance:
-4.59%
6M Performance:
+992.50%
1Y Performance:
+70.70%
1-Day Range:
$4.28
$4.98
1-Week Range:
$4.22
$5.60
52-Week Range:
$0.3901
$12.30
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
-
Address
-
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.37 | 92.74M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
3 Key Healthcare Conferences Where CAMP4 Therapeutics Will Share Its regRNA Innovation - StockTitan
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CAMP4 Therapeutics CEO to Present Corporate Update at J.P. Morgan Healthcare Conference - StockTitan
Strategic Investment Boosts Exploration Plans in Ontario's Gold Camp - Streetwise Reports
Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25 - TipRanks
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones - The Manila Times
CAMP4 Therapeutics Advances Urea Cycle Disorder Drug After $82M IPO, Secures BioMarin Partnership - StockTitan
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
CAMP4 Therapeutics to Present at Piper Sandler Healthcare Conference in NYC | CAMP Stock News - StockTitan
CAMP4 Reports Third Quarter 2024 Financial Results - The Manila Times
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Camp4 Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CAMP4 Therapeutics Secures $370M BioMarin Deal, Raises $82M in IPO Milestone | CAMP Stock News - StockTitan
CalAmp Files Bankruptcy to Complete Debt Restructuring - MSN
Camp4 gains after earning bullish views on Street - MSN
Biopharma IPOs raise nearly $1B in October from 5 public debuts - BioWorld Online
William Blair Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
October IPOs in Biotech, Cleantech, Transportation, Retail and Homebuilder Sectors - Investorideas.com newswire
Camp4 Therapeutics initiated with an Overweight at Piper Sandler - MSN
JP Morgan Initiates Coverage of Camp4 Therapeutics (CAMP) with Overweight Recommendation - MSN
JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech - Investing.com Australia
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
Camp4 stock gains after earning bullish views (CAMP:NASDAQ) - Seeking Alpha
William Blair upbeat on CAMP4 shares with Outperform rating - Investing.com
William Blair upbeat on CAMP4 shares with Outperform rating By Investing.com - Investing.com Canada
Leerink sets stock target for CAMP4, cites broad UCD treatment potential - Investing.com India
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology - Investing.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Internet of Things (IoT) in Construction Market Worth Over $61.7 Billion by 2030Industry Analysis and Forecast with Profiles of 37 Major Companies Including Autodesk, Calamp Corp, Caterpillar, Dronedeploy - GlobeNewswire
(PDF) The Effectiveness of Incarceration‐Based Drug Treatment on Criminal Behavior: A Systematic Review - ResearchGate
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Camp4 Therapeutics sees $8.4 million stock purchase by Northpond Ventures - Investing.com India
Camp4 Therapeutics sees $7.99m stock purchase by investors By Investing.com - Investing.com India
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com India
CAMP4 Rings the Opening Bell - Nasdaq
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
| Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
| Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| 5AM Partners VI, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Nashat Amir | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
| Schwab Andrew J. | Director |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
2,625,145 |
| Cohenour Jason | Director |
Jun 05 '24 |
Sale |
0.83 |
8,640 |
7,176 |
0 |
| Cohenour Jason | Director |
Mar 05 '24 |
Option Exercise |
0.00 |
7,824 |
0 |
10,962 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):